JP2021523367A5 - - Google Patents
Info
- Publication number
- JP2021523367A5 JP2021523367A5 JP2020563439A JP2020563439A JP2021523367A5 JP 2021523367 A5 JP2021523367 A5 JP 2021523367A5 JP 2020563439 A JP2020563439 A JP 2020563439A JP 2020563439 A JP2020563439 A JP 2020563439A JP 2021523367 A5 JP2021523367 A5 JP 2021523367A5
- Authority
- JP
- Japan
- Prior art keywords
- drug
- bound
- quencher
- receptor
- amount
- Prior art date
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024177293A JP2025011208A (ja) | 2018-05-10 | 2024-10-09 | インビボ受容体占有率を決定するためのアッセイ |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862669442P | 2018-05-10 | 2018-05-10 | |
| US62/669,442 | 2018-05-10 | ||
| PCT/US2019/031524 WO2019217684A1 (en) | 2018-05-10 | 2019-05-09 | Assay to determine in vivo receptor occupancy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024177293A Division JP2025011208A (ja) | 2018-05-10 | 2024-10-09 | インビボ受容体占有率を決定するためのアッセイ |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021523367A JP2021523367A (ja) | 2021-09-02 |
| JP2021523367A5 true JP2021523367A5 (https=) | 2022-04-22 |
| JPWO2019217684A5 JPWO2019217684A5 (https=) | 2022-04-22 |
| JP7570925B2 JP7570925B2 (ja) | 2024-10-22 |
Family
ID=66821369
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020563439A Active JP7570925B2 (ja) | 2018-05-10 | 2019-05-09 | インビボ受容体占有率を決定するためのアッセイ |
| JP2024177293A Withdrawn JP2025011208A (ja) | 2018-05-10 | 2024-10-09 | インビボ受容体占有率を決定するためのアッセイ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024177293A Withdrawn JP2025011208A (ja) | 2018-05-10 | 2024-10-09 | インビボ受容体占有率を決定するためのアッセイ |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US12085564B2 (https=) |
| EP (1) | EP3791183B1 (https=) |
| JP (2) | JP7570925B2 (https=) |
| KR (2) | KR20250021652A (https=) |
| CN (2) | CN113804873B (https=) |
| ES (1) | ES2992942T3 (https=) |
| WO (1) | WO2019217684A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2992942T3 (en) | 2018-05-10 | 2024-12-20 | Bristol Myers Squibb Co | Assay to determine in vivo receptor occupancy |
| CN115932261B (zh) * | 2022-08-15 | 2025-07-25 | 广州医科大学附属第五医院 | 一种btk受体占有率的检测方法 |
| CN116482345B (zh) * | 2023-06-16 | 2023-09-22 | 军科正源（北京）药物研究有限责任公司 | 用于检测双靶点药物受体占有率的方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090062255A1 (en) | 2007-08-17 | 2009-03-05 | Thallion Pharmaceuticals Inc. | Tumor-targeting evaluation methodology and compounds related thereto |
| EP2596125A1 (en) | 2010-07-19 | 2013-05-29 | Cellzome Ag | In vivo method for the evaluation of a compound-target interaction |
| US10782295B2 (en) | 2013-08-13 | 2020-09-22 | The Scripps Research Institute | Cysteine-reactive ligand discovery in proteomes |
| WO2016100593A1 (en) | 2014-12-17 | 2016-06-23 | Pharmacyclics Llc | Methods and assays for quantification and normalization of kinase and ligand binding |
| ES2992942T3 (en) | 2018-05-10 | 2024-12-20 | Bristol Myers Squibb Co | Assay to determine in vivo receptor occupancy |
-
2019
- 2019-05-09 ES ES19729943T patent/ES2992942T3/es active Active
- 2019-05-09 US US17/051,466 patent/US12085564B2/en active Active
- 2019-05-09 CN CN202110955643.1A patent/CN113804873B/zh active Active
- 2019-05-09 KR KR1020257003448A patent/KR20250021652A/ko active Pending
- 2019-05-09 CN CN201980031353.9A patent/CN112105930B/zh active Active
- 2019-05-09 JP JP2020563439A patent/JP7570925B2/ja active Active
- 2019-05-09 KR KR1020207035120A patent/KR102764357B1/ko active Active
- 2019-05-09 WO PCT/US2019/031524 patent/WO2019217684A1/en not_active Ceased
- 2019-05-09 EP EP19729943.1A patent/EP3791183B1/en active Active
-
2024
- 2024-07-31 US US18/791,084 patent/US20250085279A1/en active Pending
- 2024-10-09 JP JP2024177293A patent/JP2025011208A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012019790A5 (https=) | ||
| JP2010518847A5 (https=) | ||
| JP2011515497A5 (https=) | ||
| JP2019113564A (ja) | 多重特異性結合物の結合パートナーを検出するための方法 | |
| KR20160051887A (ko) | 신장 질환을 검출하기 위한 방법 | |
| JP2021523367A5 (https=) | ||
| US9459263B2 (en) | VEGF-A121 assay | |
| CN110546506B (zh) | 改进的免疫原性测定法 | |
| Saita et al. | An ultra-specific and sensitive sandwich ELISA for imatinib using two anti-imatinib antibodies | |
| van Schouwenburg et al. | Using monoclonal antibodies as an international standard for the measurement of anti-adalimumab antibodies | |
| CN107110853A (zh) | 确定TNFα抑制药及其相应抗药抗体的量的通用测定法 | |
| JP2013536419A5 (https=) | ||
| US7842456B2 (en) | Reagents, kits and methods for immunodetection of epitopes on molecules | |
| WO2018194152A1 (ja) | アルドステロン及びレニンの検出方法 | |
| JP2019507866A (ja) | 血漿バイオマーカーのレベルを測定することによる、がんに罹患していることが疑われる患者のアフリベルセプトによる治療の転帰を予測するための方法 | |
| CN108738347B (zh) | 辅助肝细胞癌患者的再发风险预测的方法、装置、计算机程序制品及试剂盒 | |
| KR20100074743A (ko) | 초고속 스크리닝용 단백질칩 시스템을 이용한 항체모방 펩타이드 탐색방법 | |
| Wang et al. | An apparent clinical pharmacokinetic drug–drug interaction between bevacizumab and the anti-placental growth factor monoclonal antibody RO5323441 via a target-trapping mechanism | |
| JPWO2019217684A5 (https=) | ||
| CN118043666A (zh) | 对定量药物和靶标浓度的测定 | |
| EP2943792B1 (en) | A method for predicting the risk of getting cancer or diagnosing cancer in a subject | |
| US11415584B2 (en) | Biomarkers, test method, and test kit for predicting therapeutic effect of anti-VEGFR-2 antibody drug | |
| JP6901731B2 (ja) | 膵臓癌の検査方法 | |
| US20200018750A1 (en) | Methods and compositions for the prediction and treatment of focal segmental glomerulosclerosis | |
| Sluss et al. | Laboratory techniques for recognition of endocrine disorders |